0000000000261276

AUTHOR

Taylor Brackin

showing 2 related works from this author

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Tri…

2021

Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 mg twice daily plus aspirin or matching placebo plus aspirin and followed …

Lower extremity revascularizationMalemedicine.medical_specialtylower extremity revascularization; major adverse cardiovascular events (MACE); major adverse limb events (MALE); peripheral artery disease; revascularization; rivaroxaban.lower extremity revascularizationArterial diseasemedicine.medical_treatmentDiseaseRevascularizationperipheral artery diseasePeripheral Arterial DiseaseRivaroxabanPhysiology (medical)Internal medicinemedicineHumansIn patientmajor adverse cardiovascular events (MACE)major adverse limb events (MALE)AgedRivaroxabanAspirinAspirinbusiness.industryMiddle AgedCardiologyrevascularizationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugSurgical revascularizationCirculation
researchProduct

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization

2021

Abstract Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety and effectiveness in LER for PAD. Methods VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespe…

Rivaroxabanmedicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentThrombolysisRevascularizationPlacebomedicine.diseasechemistry.chemical_compoundPaclitaxelchemistryInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugJournal of the American College of Cardiology
researchProduct